# Orchestra BioMed Holdings Inc. (OBIO) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $5.08, market value $305 million.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Orchestra BioMed Holdings Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 9.5×**. Each dollar of revenue is priced at 9.5×.
- **Price / book: 15.8×**. The shares trade at 15.8× book value; most of the value is in earnings power and intangibles rather than the balance sheet.
- **Free-cash-flow yield: -19.4%** (5-yr avg -23.7%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Operating margin: -181.4%**. Operating margin is negative: the business loses money before interest and tax.
- **Net margin: -157.4%**. The company reported a net loss over the last twelve months.
- **Return on equity: -98.4%**. Return on equity is negative because earnings are negative.
- **Return on invested capital: -135.2%**. Return on all capital, debt included, is -135.2%: close to or below the cost of capital, so growth may not create value.
- **Return on assets: -51.4%**. Each dollar of assets produces -51.4% of profit.

## Growth
- **Revenue growth (1 yr): 1169.2%** (3-yr 111.6%/yr). Revenue grew 1169.2% over the last year.
- **EPS growth (1 yr): 33.1%**. Earnings per share rose 33.1%, slower than revenue, so margins compressed.

## Financial health
- **Debt to equity: 0.28**. Debt is 0.28 times equity: a conservative balance sheet.
- **Net debt / EBITDA: 0.3×**. It would take 0.3 years of operating earnings to repay net borrowings, within the comfortable range.
- **Altman Z-score: 3.01**. A Z-score of 3.01 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 4/9**. 4 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. Orchestra BioMed Holdings Inc. does not currently pay a dividend.

## Price and momentum
- **Total return (1 yr): 85.4%** (YTD 22.4%, 3-mo 30.3%). The shares are up 85.4% over twelve months including dividends.
- **From 52-week high: -12.1%** (130.9% above the low). Trading 12% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 57**. An RSI of 57 is neutral.
- **Beta (1 yr): 1.46** (volatility 68%). Beta of 1.46 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=OBIO · Page: https://foliofundamentals.com/stocks/obio

Not investment advice.